2007
898: Fractional Percentage of Tumor Volume Removed Predicts Outcome Following Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
Pierorazio P, McKiernan J, McCann T, Mohile S, Petrylak D, Benson M. 898: Fractional Percentage of Tumor Volume Removed Predicts Outcome Following Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. Journal Of Urology 2007, 177: 298. DOI: 10.1016/s0022-5347(18)31126-1.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaRenal cell carcinomaCytoreductive nephrectomyCell carcinomaPredicts outcomeTumor volume
2004
A phase II multicenter study of the cyclin-dependent kinase inhibitor indisulam in patients with progressive inoperable and/or metastatic renal cell carcinoma (RCC)
Raftopoulos H, Escudier B, Renshaw G, Lara P, Dutcher J, Nanus D, Petrylak D, Sacris L. A phase II multicenter study of the cyclin-dependent kinase inhibitor indisulam in patients with progressive inoperable and/or metastatic renal cell carcinoma (RCC). Journal Of Clinical Oncology 2004, 22: 4629-4629. DOI: 10.1200/jco.2004.22.14_suppl.4629.Peer-Reviewed Original ResearchRenal cell carcinomaPhase II multicenter studyMetastatic renal cell carcinomaMulticenter studyCell carcinomaPatientsCarcinomaA phase II multicenter study of the cyclin-dependent kinase inhibitor indisulam in patients with progressive inoperable and/or metastatic renal cell carcinoma (RCC)
Raftopoulos H, Escudier B, Renshaw G, Lara P, Dutcher J, Nanus D, Petrylak D, Sacris L. A phase II multicenter study of the cyclin-dependent kinase inhibitor indisulam in patients with progressive inoperable and/or metastatic renal cell carcinoma (RCC). Journal Of Clinical Oncology 2004, 22: 4629-4629. DOI: 10.1200/jco.2004.22.90140.4629.Peer-Reviewed Original ResearchRenal cell carcinomaPhase II multicenter studyMetastatic renal cell carcinomaMulticenter studyCell carcinomaPatientsCarcinoma
2000
A Phase II Pilot Study of KW-2189 in Patients with Advanced Renal Cell Carcinoma
Small E, Figlin R, Petrylak D, Vaughn D, Sartor O, Horak I, Pincus R, Kremer A, Bowden C. A Phase II Pilot Study of KW-2189 in Patients with Advanced Renal Cell Carcinoma. Investigational New Drugs 2000, 18: 193-198. PMID: 10857997, DOI: 10.1023/a:1006386115312.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaMetastatic renal cell carcinomaCell carcinomaOpen-label phase II trialCommon drug-related toxicitiesAdvanced renal cell carcinomaPhase II pilot studyNon-hematologic toxicitiesPhase II trialDrug-related toxicityPredictable safety profileReversible myelosuppressionII trialObjective responseSafety profileDisease progressionModerate fatigueWeek 6PatientsSignificant toxicityCarcinomaPilot studyAntitumor potencyWater-soluble analogueCycle 1
1989
Interleukin‐2 enhances biopterins and catecholamines production during adoptive immunotherapy for various cancers
Baker H, Marcus S, Frank O, Petrylak D, Deangelis B, Dutcher J, Wiernik P. Interleukin‐2 enhances biopterins and catecholamines production during adoptive immunotherapy for various cancers. Cancer 1989, 64: 1226-1231. PMID: 2788491, DOI: 10.1002/1097-0142(19890915)64:6<1226::aid-cncr2820640611>3.0.co;2-m.Peer-Reviewed Original ResearchConceptsIL-2 treatmentAdoptive immunotherapyInterleukin-2Biopterin productionPlasma biopterinMetastatic renal cell carcinomaIL-2 activationIL-2 exposureAdoptive immunotherapy protocolsMetastatic colon cancerRenal cell carcinomaLAK treatmentImmunotherapy protocolsKiller cellsLAK cellsImmunotherapy treatmentCell carcinomaPlasma catecholaminesTumor regressionCatecholamine productionMalignant melanomaLeukocyte populationsTotal biopterinLeukocyte activationImmunotherapy